Table of Content

Executive Summary

1 Product Definition
1.1 Inclusion and Exclusion

2 Market Scope
2.1 Scope of Work
2.2 Key Questions Answered in the Report

3 Research Methodology
3.1 Global Oncolytic Virus Therapies Market: Research Methodology
3.2 Primary Data Sources
3.3 Secondary Data Sources
3.4 Market Estimation Model
3.5 Criteria for Company Profiling

4 Market Overview
4.1 Market Definition
4.2 Importance of Oncolytic Virus Therapies in Cancer Treatment
4.3 Market Size and Growth Potential, $Million, 2019-2030
4.4 COVID-19 Impact on the Global Oncolytic Virus Therapies Market

5 Industry Insights
5.1 Overview
5.2 Regulatory Scenario
5.3 Legal Requirements and Framework in the U.S
5.3.1 Clinical Trial Authorization
5.3.2 U.S. FDA Guidelines for BLA Submission
5.4 Legal Requirements and Framework in Europe
5.4.1 EMA Biologics License Application Process
5.4.2 Centralized Procedure
5.4.3 Decentralized Procedure
5.4.4 Mutual-Recognition Procedure
5.5 Legal Requirements and Framework in Asia-Pacific
5.5.1 China
5.5.2 Japan
5.6 Expedited Regulatory Designations Around the World
5.7 Reimbursement Scenario
5.8 Patent Analysis
5.8.1 Patent Filing Trend

6 Market Dynamics
6.1 Overview
6.2 Impact Analysis
6.3 Market Drivers
6.3.1 Increasing Incidence of Cancer
6.3.2 Rising Number of Clinical Trials
6.3.3 Increasing Research Funding from National Cancer Institute
6.3.4 Increasing Adoption of Inorganic Growth Strategies in the Market
6.4 Market Restrains
6.4.1 High Cost of Therapy
6.4.2 Lack of Therapy-Specific Assays
6.5 Market Opportunities
6.5.1 Opportunities in the Emerging Economies
6.5.2 Drug Approvals and Strong Pipeline of Oncolytic Virus Therapies

7 Competitive Landscape
7.1 Synergistic Activities
7.2 Business Expansion Activities and Others
7.3 Product Launches and Product Updates
7.4 Mergers and Acquisitions
7.5 Market Share Analysis
7.6 Growth Share Analysis
7.6.1 Growth Share Analysis (by Commercialized Therapy)

8 Oncolytic Virus Therapies: Epidemiology Analysis

9 Global Oncolytic Virus Therapies Market (by Commercialized Therapies), $Million, 2019-2030
9.1 Overview
9.2 Imlygic
9.3 Oncorine
9.4 RIGVIR

10 Global Oncolytic Virus Therapies Market (by Pipeline Therapies), $Million, 2019-2030
10.1 Overview
10.2 Phase I
10.3 Phase II
10.4 Phase III
10.5 Phase IV

11 Global Oncolytic Virus Therapies Market (by Type of Virus), $Million, 2019-2030
11.1 Overview
11.2 Genetically Engineered Oncolytic Virus
11.2.1 Herpes Simplex Virus (HSV)
11.2.2 Adenovirus
11.2.3 Vaccinia Virus
11.3 Oncolytic Wild-Type Virus
11.3.1 Reovirus (Respiratory Enteric Orphan Virus)
11.3.2 Newcastle Disease Virus (NDV)
11.3.3 Vesicular Stomatitis Virus (VSV)

12 Global Oncolytic Virus Therapies Market (by Application), $Million, 2019-2030
12.1 Overview
12.2 Solid Tumor
12.2.1 Breast Cancer
12.2.2 Prostate Cancer
12.2.3 Lung Cancer
12.2.4 Glioblastoma
12.2.5 Melanoma
12.2.6 Other Applications
12.3 Hematological Malignancies
12.3.1 Lymphoma
12.3.2 Leukemia
12.3.3 Myeloma

13 Global Oncolytic Virus Therapies Market (by Region), $Million, 2019-2030
13.1 Overview
13.2 North America
13.2.1 U.S.
13.3 Europe
13.3.1 U.K.
13.3.2 Latvia
13.3.3 Georgia
13.3.4 Armenia
13.3.5 Germany
13.3.6 France
13.3.7 Italy
13.3.8 Rest-of-Europe
13.4 Asia-Pacific
13.4.1 China
13.4.2 Japan
13.4.3 Rest-of-APAC

14 Company Profiles
14.1 Overview
14.2 Amgen Inc.
14.2.1 Company Overview
14.2.2 Role of Amgen Inc. in the Global Oncolytic Virus Therapies Market
14.2.3 Financials
14.2.4 Key Insights about Financial Health of the Company
14.2.5 SWOT Analysis
14.3 DAIICHI SANKYO COMPANY, LIMITED
14.3.1 Company Overview
14.3.2 Role of DAIICHI SANKYO COMPANY, LIMITED in the Global Oncolytic Virus Therapies Market
14.3.3 Financials
14.3.4 Key Insights About Financial Health of the Company
14.3.5 SWOT Analysis
14.4 DNAtrix
14.4.1 Company Overview
14.4.2 Role of DNAtrix in the Global Oncolytic Virus Therapies Market
14.4.3 SWOT Analysis
14.5 Genelux
14.5.1 Company Overview
14.5.2 Role of Genelux in the Global Oncolytic Virus Therapies Market
14.5.3 SWOT Analysis
14.6 Oncolytics Biotech, Inc.
14.6.1 Company Overview
14.6.2 Role of Oncolytics Biotech, Inc. in the Global Oncolytic Virus Therapies Market
14.6.3 Financials
14.6.4 SWOT Analysis
14.7 PsiOxus Therapeutics
14.7.1 Company Overview
14.7.2 Role of PsiOxus Therapeutics in the Global Oncolytic Virus Therapies Market
14.7.3 SWOT Analysis
14.8 RIGVIR Ltd.
14.8.1 Company Overview
14.8.2 Role of RIGVIR Ltd. in the Global Oncolytic Virus Therapies Market
14.8.3 SWOT Analysis
14.9 Shanghai Sunway Biotech Co., Ltd.,
14.9.1 Company Overview
14.9.2 Role of Shanghai Sunway Biotech Co., Ltd., in the Global Oncolytic Virus Therapies Market
14.9.3 SWOT Analysis
14.1 SillaJen, Inc.
14.10.1 Company Overview
14.10.2 Role of SillaJen, Inc. in the Global Oncolytic Virus Therapies Market
14.10.3 SWOT Analysis
14.11 Sorrento Therapeutics, Inc.
14.11.1 Company Overview
14.11.2 Role of Sorrento Therapeutics, Inc. in Global Oncolytic Virus Therapies Market
14.11.3 Financials
14.11.4 Key Insights About Financial Health of the Company
14.11.5 SWOT Analysis
14.12 Takara Bio Inc.
14.12.1 Company Overview
14.12.2 Role of Takara Bio Inc. in the Global Oncolytic Virus Therapies Market
14.12.3 Financials
14.12.4 Key Insights About Financial Health of the Company
14.12.5 SWOT Analysis
14.13 Transgene sa
14.13.1 Company Overview
14.13.2 Role of Transgene sa in the Global Oncolytic Virus Therapies Market
14.13.3 Financials
14.13.4 SWOT Analysis
14.14 VCNBiosciences
14.14.1 Company Overview
14.14.2 Role of VCNBiosciences in the Global Oncolytic Virus Therapies Market
14.14.3 SWOT Analysis
14.15 ViroCure
14.15.1 Company Overview
14.15.2 Role of ViroCure in the Global Oncolytic Virus Therapies Market
14.15.3 SWOT Analysis
14.16 Viralytics Ltd. (Merck & Co., Inc.)
14.16.1 Company Overview
14.16.2 Role of Merck & Co., Inc. in the Global Oncolytic Virus Therapies Market
14.16.3 Financials
14.16.4 Key Insights About Financial Health of the Company
14.16.5 SWOT Analysis
 



List of Tables
Table 5.1: Regulatory Scenario Across the World
Table 5.2: Expedited Regulatory Designations Around the World
Table 5.3: Key Market Access Landscape (by Country), January 2019
Table 9.1: Commercialized Therapies
Table 10.1: Key Oncolytic Virus Therapies in Clinical Development Phase I, 2020
Table 10.2: Key Oncolytic Virus Therapies in Clinical Development Phase II, 2020
Table 10.3: Key Oncolytic Virus Therapies in Clinical Development Phase III, 2020
Table 11.1: Key Herpes Simplex Virus (HSV)-Based Oncolytic Therapies
Table 11.2: Key Adenovirus-Based Oncolytic Therapies
Table 11.3: Key Vaccinia Virus-Based Oncolytic Therapies
Table 11.4: Key Reovirus-Based Oncolytic Therapies
Table 13.1: Rest-of-APAC - Pipeline Drugs
List of Figures
Figure 1: NCI Fiscal Budget Year on Year, 2013-2018
Figure 2: Impact Analysis of Market Drivers and Market Challenges on the Global Oncolytic Virus Therapies Market
Figure 3: Global Oncolytic Virus Therapies Market (by Application), $Million, 2019 Vs. 2030
Figure 4: Global Oncolytic Virus Therapies Market (by Type of Virus), $Million, 2019 vs. 2030
Figure 5: Global Oncolytic Virus Therapies Market Snapshot, $Million, 2019 and 2030
Figure 2.1: Global Oncolytic Virus Therapies Market Segmentation
Figure 3.1: Global Oncolytic Virus Therapies Market Research Methodology
Figure 3.2: Primary Research Methodology
Figure 3.3: Bottom-Up Approach (Segment-Wise Analysis)
Figure 3.4: Top-Down Approach (Segment-Wise Analysis)
Figure 4.1: Global Oncolytic Virus Therapies Market, $Million, 2019-2030
Figure 4.2: Global Oncolytic Virus Therapies Market: COVID-19 Impact
Figure 5.1: Clinical Trial Authorization for Oncolytic Virus Therapies
Figure 5.2: Steps for Obtaining Marketing Authorization
Figure 5.3: U.S. FDA Expedited Review Programs
Figure 5.4: Regulatory Strategy for Oncolytic Virus Therapies in the U.S.
Figure 5.5: U.S.FDA Review Timeline
Figure 5.6: Regulatory Strategy for Oncolytic Virus Therapies in Europe
Figure 5.7: EMA Review Timeline
Figure 5.9: Overview of PMDA and MLHW Drug Approval Process in Japan
Figure 5.10: Global Oncolytic Virus Therapies Market: Patent Analysis (by Country and Year), January 2015-March 2021
Figure 6.1: Impact Analysis
Figure 6.2: Cancer Cases Projection, 2016-2020
Figure 6.3: Number of Active and Completed Clinical Trials for Gene Therapy (by Start Date), 2015-2019
Figure 6.4: SBIR and STTR Grants and Contract Funding, 2008-2018
Figure 6.5: NCI Fiscal Budget Year-on-Year, 2013-2018
Figure 6.6: Synergistic Activities, 2018-2020
Figure 7.1: Share of Key Developments and Strategies, January 2018-March 2021
Figure 7.2: Synergistic Activities Share (by Company), January 2018-March 2021
Figure 7.3: Business Expansion Activities Share (by Company), January 2018-March 2021
Figure 7.4: Number of Product Launches (by Company), January 2018-March 2021
Figure 7.5: Mergers and Acquisitions, January 2018-March 2021
Figure 7.6: Market Share Analysis for Global Oncolytic Virus Therapies Market, (by Application), $Million, 2020
Figure 7.7: Growth Share Analysis for Global Oncolytic Virus Therapies Market (by Commercialized Therapy), 2019-2020
Figure 8.1: Type of Cancer
Figure 8.2: Global Estimated Percent of New Cancer Cases (by Sex), 2030
Figure 8.3: Expected Cancer Cases in the World (by Country), 2030
Figure 8.4: Relative Number of Expected New Cancer Cases (by Country), 2030
Figure 9.1: Global Oncolytic Virus Therapies Market (Imlygic), $Million, 2019-2030
Figure 9.2: Global Oncolytic Virus Therapies Market (Oncorine), $Million, 2019-2030
Figure 9.3: Global Oncolytic Virus Therapies Market (RIGVIR), $Million, 2019-2030
Figure 10.1: Oncolytic Virus Gene Therapy Medicines in Development (by Disease), 2019
Figure 11.1: Global Oncolytic Virus Therapies Market (by Type of Virus), $Million, 2019-2030
Figure 11.2: Global Oncolytic Virus Therapies Market (by Genetically Engineered Oncolytic Virus), $Million, 2019 and 2030
Figure 11.3: Global Oncolytic Virus Therapies Market (Herpes Simplex Virus), $Million, 2019-2030
Figure 11.4: Global Oncolytic Virus Therapies Market (Adenovirus), $Million, 2019-2030
Figure 11.5: Global Oncolytic Virus Therapies Market (Vaccinia Virus), $Million, 2019-2030
Figure 11.6: Global Oncolytic Virus Therapies Market (by Oncolytic Wild-Type Virus), $Million, 2019 and 2030
Figure 11.7: Global Oncolytic Virus Therapies Market (Reovirus), $Million, 2019-2030
Figure 11.8: Global Oncolytic Virus Therapies Market (Newcastle Disease Virus), $Million, 2019-2030
Figure 11.9: Global Oncolytic Virus Therapies Market (Vesicular Stomatitis Virus), $Million, 2019-2030
Figure 12.1: Global Oncolytic Virus Therapies Market (by Application), $Million, 2019-2030
Figure 12.2: Global Oncolytic Virus Therapies Market (by Solid Tumor), $Million, 2019 and 2030
Figure 12.3: Global Oncolytic Virus Therapies Market (Breast Cancer), $Million, 2019-2030
Figure 12.4: Global Oncolytic Virus Therapies Market (Prostate Cancer), $Million, 2019-2030
Figure 12.5: Global Oncolytic Virus Therapies Market (Lung Cancer), $Million, 2019-2030
Figure 12.6: Global Oncolytic Virus Therapies Market (Glioblastoma), $Million, 2019-2030
Figure 12.7: Global Oncolytic Virus Therapies Market (Melanoma), $Million, 2019-2030
Figure 12.8: Global Oncolytic Virus Therapies Market (Other Applications), $Million, 2019-2030
Figure 12.9: Global Oncolytic Virus Therapies Market (by Haematological Malignancies), $Million, 2019 and 2030
Figure 12.10: Global Oncolytic Virus Therapies Market (Lymphoma), $Million, 2019-2030
Figure 12.11: Global Oncolytic Virus Therapies Market (Leukemia), $Million, 2019-2030
Figure 12.12: Global Oncolytic Virus Therapies Market (Myeloma), $Million, 2019-2030
Figure 13.1: Global Oncolytic Virus Therapies Market (by Region), 2019-2030
Figure 13.2: Global Oncolytic Virus Therapies Market (by Region), $Million, 2019-2030
Figure 13.3: Global Oncolytic Virus Therapies Market Share (by Region), $Million, 2019
Figure 13.4: Global Oncolytic Virus Therapies Market Share (by Region), $Million, 2030
Figure 13.5: North America Oncolytic Virus Therapies Market, $Million, 2019-2030
Figure 13.6: North America: Market Dynamics
Figure 13.7: U.S. Oncolytic Virus Therapies Market, $Million, 2019-2030
Figure 13.8: Europe Oncolytic Virus Therapies Market, $Million, 2019-2030
Figure 13.9: Europe: Market Dynamics
Figure 13.10: Europe Oncolytic Virus Therapies Market (by Country), $Million, 2019-2030
Figure 13.11: U.K. Oncolytic Virus Therapies Market, $Million, 2019-2030
Figure 13.12: Latvia Oncolytic Virus Therapies Market, $Million, 2019-2030
Figure 13.13: Georgia Oncolytic Virus Therapies Market, $Million, 2019-2030
Figure 13.14: Armenia Oncolytic Virus Therapies Market, $Million, 2019-2030
Figure 13.15: Germany Oncolytic Virus Therapies Market, $Million, 2019-2030
Figure 13.16: France Oncolytic Virus Therapies Market, $Million, 2019-2030
Figure 13.17: Italy Oncolytic Virus Therapies Market, $Million, 2019-2030
Figure 13.18: Rest-of-Europe Oncolytic Virus Therapies Market, $Million, 2019-2030
Figure 13.19: Asia-Pacific Oncolytic Virus Therapies Market, $Million, 2019-2030
Figure 13.20: APAC: Market Dynamics
Figure 13.21: APAC Oncolytic Virus Therapies Market (by Country), $Million, 2019-2030
Figure 13.22: China Oncolytic Virus Therapies Market, $Million, 2019-2030
Figure 13.23: Japan Oncolytic Virus Therapies Market, $Million, 2019-2030
Figure 13.24: RoAPAC Oncolytic Virus Therapies Market, $Million, 2019-2030
Figure 14.1: Total Number of Companies Profiled
Figure 14.2: Amgen Inc.: Product Portfolio
Figure 14.3: Amgen Inc.: Overall Financials, $Million, 2018-2020
Figure 14.4: Amgen Inc.: Revenue (by Region), $Million, 2018-2020
Figure 14.5: Amgen Inc. R&D Expenditure, $Billion, 2018-2020
Figure 14.6: Amgen Inc.: SWOT Analysis
Figure 14.7: DAIICHI SANKYO COMPANY, LIMITED: Product Portfolio
Figure 14.8: DAIICHI SANKYO COMPANY, LIMITED: Overall Financials, $Billion, 2017-2019
Figure 14.9: Amgen Inc. R&D Expenditure, $Billion, 2017-2019
Figure 14.10: DAIICHI SANKYO COMPANY, LIMITED: SWOT Analysis
Figure 14.11: DNAtrix: Product Portfolio
Figure 14.12: DNAtrix: SWOT Analysis
Figure 14.13: Genelux: Product Portfolio
Figure 14.14: Genelux: SWOT Analysis
Figure 14.15: Oncolytics Biotech, Inc.: Product Portfolio
Figure 14.16: Oncolytics Biotech, Inc.: SWOT Analysis
Figure 14.17: PsiOxus Therapeutics: Pipeline Product Portfolio
Figure 14.18: PsiOxus Therapeutics: SWOT Analysis
Figure 14.19: RIGVIR Ltd.: Overall Service Portfolio
Figure 14.20: RIGVIR Ltd.: SWOT Analysis
Figure 14.21: Product Portfolio: Shanghai Sunway Biotech Co., Ltd.,
Figure 14.22: Shanghai Sunway Biotech Co., Ltd.: SWOT Analysis
Figure 14.23: SillaJen, Inc.: Product Portfolio
Figure 14.24: SillaJen, Inc.: SWOT Analysis
Figure 14.25: Sorrento Therapeutics, Inc.: Product Portfolio
Figure 14.26: Sorrento Therapeutics, Inc.: Overall Financials, 2017-2019
Figure 14.27: Sorrento Therapeutics, Inc. R&D Expenditure, $Million, 2017-2019
Figure 14.28: Sorrento Therapeutics, Inc.: SWOT Analysis
Figure 14.29: Takara Bio Inc.: Product Portfolio
Figure 14.30: Takara Bio Inc.: Overall Financials, 2017-2019
Figure 14.31: Takara Bio Inc.: Revenue (by Segment), $Million, 2017-2019
Figure 14.32: Takara Bio Inc.: Revenue (by Region), $Million, 2017-2019
Figure 14.33: Takara Bio Inc.: R&D Expenditure, 2017-2019
Figure 14.34: Takara Bio Inc.: SWOT Analysis
Figure 14.35: Transgene sa: Product Portfolio
Figure 14.36: Transgene sa: Overall Financials, $Million, 2017-2019
Figure 14.37: Transgene sa: SWOT Analysis
Figure 14.38: VCNBiosciences: Pipeline Product Portfolio
Figure 14.39: VCNBiosciences: SWOT Analysis
Figure 14.40: ViroCure: Product Portfolio
Figure 14.41: ViroCure: SWOT Analysis
Figure 14.42: Viralytics Ltd., (Merck & Co., Inc.): Product Portfolio
Figure 14.43: Merck & Co., Inc.: Overall Financials, $Million, 2018-2020
Figure 14.44: Merck & Co., Inc.: Revenue (by Segment), $Million, 2018-2020
Figure 14.45: Merck & Co., Inc.: Revenue (by Region), $Million, 2018-2020
Figure 14.46: Merck & Co., Inc.: R&D Expenditure, $Million, 2018-2020
Figure 14.47: Merck & Co., Inc.: SWOT Analysis